← Back to Clinical Trials
Recruiting NCT02994121

NCT02994121 Prospective Investigation of Multiple Sclerosis in the Three Rivers Region

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02994121
Status Recruiting
Phase
Sponsor University of Pittsburgh
Condition Multiple Sclerosis
Study Type OBSERVATIONAL
Enrollment 7,500 participants
Start Date 2016-12
Primary Completion 2047-01

Eligibility & Interventions

Sex All sexes
Min Age 7 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 7,500 participants in total. It began in 2016-12 with a primary completion date of 2047-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In this longitudinal prospective natural history study of multiple sclerosis (MS), the overarching goal is to understand the factors that influence individual variation in disease trajectory and treatment response and pave the way for realizing precision medicine in MS. Because MS is a chronic neurological disorder, this observational cohort study will span a 30-year time frame.

Eligibility Criteria

Inclusion Criteria: * Inclusion criteria for MS patients include: 1. Age 7 years or older 2. Willing and able to provide consent (for \>=18 years) or assent with permission from at least one of the child's parents (for \<18 years) 3. Diagnosis of multiple sclerosis or related disorders, including a first central nervous system demyelinating episode with a positive MRI scan or abnormal MRI scans characteristic of MS but no clinical symptoms of the disease * For healthy controls: 1. Age 7 years or older 2. Willing and able to provide consent (for \>=18 years) or assent with permission from at least one of the child's parents (for \<18 years) 3. No known personal history of multiple sclerosis or related disorders 4. No other chronic diseases 5. Family members, unrelated household controls, or controls from the general population could be eligible There is no exclusion criteria.

Contact & Investigator

Central Contact

Zongqi Xia, MD, PhD

✉ msstudy2@pitt.edu

📞 412-383-5377

Principal Investigator

Zongqi Xia, MD, PhD

PRINCIPAL INVESTIGATOR

University of Pittsburgh

Frequently Asked Questions

Who can join the NCT02994121 clinical trial?

This trial is open to participants of all sexes, aged 7 Years or older, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT02994121 currently recruiting?

Yes, NCT02994121 is actively recruiting participants. Contact the research team at msstudy2@pitt.edu for enrollment information.

Where is the NCT02994121 trial being conducted?

This trial is being conducted at Pittsburgh, United States.

Who is sponsoring the NCT02994121 clinical trial?

NCT02994121 is sponsored by University of Pittsburgh. The principal investigator is Zongqi Xia, MD, PhD at University of Pittsburgh. The trial plans to enroll 7,500 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology